HIMS Stock More Than Doubled in 6 Months: What's Driving the Rally?

Hims & Hers Health HIMS stock has surged 105.4% over the past six months, dramatically outperforming the healthcare industry and the S&P 500’s growth of 45.8% and 12.5%, respectively.

Second-quarter revenues jumped nearly 40% year over year to $753 million, while Hims & Hers added 300,000 net subscribers to reach nearly three million. U.S. revenue growth also accelerated to 16%, helped by the company’s March pivot toward branded weight-loss offerings. The stock, which more than doubled in just six months, reflects a sharp improvement in the company’s growth trajectory after a slower start to 2026.

Meanwhile, international expansion and AI-driven personalization are broadening the platform beyond weight loss. The Zacks Consensus Estimate for sales for 2026 implies an improvement of 37.2%.

Image Source: Zacks Investment Research

Factors That Drove the Rally

Branded Weight-Loss Expansion Is Reaccelerating U.S. Growth: The decision taken by HIMS in March to broaden branded weight-loss offerings has become a major catalyst. Hims & Hers fulfilled more than 125,000 Wegovy shipments within six weeks of launching direct access to Novo Nordisk’s products, while customers have responded positively to the Wegovy pill. The company also added access to Eli Lilly’s Zepbound and Foundayo. Management expects the resulting subscriber cohorts and monthly cadence to accelerate U.S. revenues and EBITDA in the second half.

International Expansion Is Rapidly Increasing the Addressable Market: International operations are becoming a meaningful growth engine. Revenues outside the United States surged more than 17-fold year over year to $131 million in the second quarter, including approximately $40 million from Eucalyptus. International revenues also surged 68% sequentially. The United Kingdom, Australia and Germany each exceed $100 million in annualized revenues, while Canada is approaching that threshold, providing substantial room for expansion.

AI Is Improving Engagement While Lowering the Cost to Serve: Hims & Hers’ AI strategy could strengthen retention and operating efficiency. The new AI-native care experience for Hims & Hers’ weight-loss customers has tripled messaging activity, with AI handling about 80% of questions. This has reduced nonclinical support tasks by nearly 50%. Management expects these efficiencies to pay back within 12-18 months and plans to reinvest savings into lower prices, richer tools and further customer acquisition.

Cross-Selling and New Specialties Are Increasing Customer Lifetime Value: Hims & Hers is increasingly using high-demand categories such as weight loss and sexual health as entry points to broader care. Its lab capabilities can identify needs involving low testosterone and cardiovascular health, while testosterone is expected to become the company’s sixth U.S. specialty with a $100 million annual revenue run rate. This multi-specialty model could increase retention, cross-selling and data depth while allowing Hims to serve more of each subscriber’s healthcare journey.

Competition

Hims & Hers faces competition from digital-health platforms with different strengths. Doximity DOCS reported revenues of $157 million in the first quarter of fiscal 2027, up 7% year over year. Active workflow prescribers increased more than 30%, and 165 health systems adopted its AI products. Doximity is building a strong physician-facing AI ecosystem, but its model is primarily professional-network and software-driven rather than consumer-centric. GoodRx GDRX remains a major consumer-health competitor, with Pharma Direct revenues up 76% in the second quarter, and more than 135 consumer-direct pricing programs. GoodRx also continues to benefit from GLP-1 demand and manufacturer partnerships. Tempus AI TEM reported 22% revenue growth to $382.5 million during the second quarter, driven by diagnostics, data licensing and AI-enabled oncology tools. Its acquisition of Personalis adds exposure to the fast-growing MRD testing market.

Relative to Doximity, GoodRx and Tempus AI, Hims & Hers has the strongest direct exposure to consumer subscription healthcare and weight-loss demand. Doximity has deeper physician engagement, GoodRx has extensive pharmacy and manufacturer relationships, and Tempus AI has a differentiated clinical-data platform. However, HIMS combines consumer scale, recurring subscriptions, pharmacy infrastructure and direct-care capabilities in a way that Doximity, GoodRx and Tempus AI are unlikely to replicate.

Hims & Hers Health, Inc. Revenue (Quarterly)

Hims & Hers Health, Inc. revenue-quarterly | Hims & Hers Health, Inc. Quote

Risks and Challenges

The biggest risks in the second half of 2026 are regulatory, mix and execution related. Hims & Hers expects gross margins to remain pressured as branded weight-loss products and international revenues represent a larger share of sales. The company is also increasingly dependent on regulatory developments for higher-complexity offerings, including injectable testosterone and potential peptide therapies. In addition, the strategic shift away from its previously developed compounded GLP-1 infrastructure resulted in $33 million of restructuring costs in the first quarter, highlighting the risk of rapidly changing the product mix. International expansion and the integration of Eucalyptus also raise execution requirements as HIMS scales across multiple markets simultaneously.

Conclusion

The more than doubling of Hims & Hers’ stock in just six months is supported by accelerating U.S. growth, branded GLP-1 adoption, international expansion, AI-enabled efficiency and a broader specialty portfolio. The company has raised 2026 revenue guidance to $3.1-$3.3 billion, reinforcing the momentum. However, regulatory uncertainty and margin compression warrant caution. With HIMS carrying a Zacks Rank #3 (Hold), investors should balance the powerful growth trajectory against execution and valuation risks. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research